Subject(s)
Antiviral Agents/therapeutic use , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/virology , Adenoviridae/genetics , Adenoviridae/immunology , Adenoviridae/pathogenicity , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Disease Outbreaks , Humans , Orthomyxoviridae/genetics , Orthomyxoviridae/immunology , Orthomyxoviridae/pathogenicity , Respiratory Syncytial Viruses/genetics , Respiratory Syncytial Viruses/immunology , Respiratory Syncytial Viruses/pathogenicity , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/immunology , Rhinovirus/genetics , Rhinovirus/pathogenicity , Risk Factors , Vaccines/adverse effects , Vaccines/immunology , Vaccines/therapeutic useSubject(s)
Orthomyxoviridae , Respiratory System/virology , Adenoviridae/isolation & purification , Adenoviridae/pathogenicity , Animals , Antiviral Agents/therapeutic use , Common Cold/etiology , Common Cold/immunology , Disease Reservoirs , HIV Infections/complications , Humans , Influenza, Human/drug therapy , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Orthomyxoviridae/genetics , Orthomyxoviridae/immunology , Respiratory Syncytial Viruses/immunology , Respiratory Syncytial Viruses/pathogenicity , Tissue Transplantation/adverse effects , VaccinationSubject(s)
Influenza, Human , Respiratory Tract Infections/virology , Animals , Antiviral Agents/therapeutic use , Hawaii , Humans , Influenza A virus/immunology , Influenza A virus/pathogenicity , Influenza Vaccines/immunology , Influenza, Human/diagnosis , Influenza, Human/drug therapy , Influenza, Human/epidemiology , Influenza, Human/immunology , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/immunologySubject(s)
Hepatitis B, Chronic/therapy , Hepatitis C, Chronic/therapy , Hepatitis, Viral, Human/therapy , Animals , Disease Models, Animal , Hepatitis B, Chronic/immunology , Hepatitis C, Chronic/immunology , Hepatitis, Viral, Animal/immunology , Hepatitis, Viral, Animal/therapy , Hepatitis, Viral, Human/immunology , HumansSubject(s)
Norepinephrine/physiology , Obesity/epidemiology , Proteins/physiology , Appetite Depressants/therapeutic use , Behavior Therapy , Cyclobutanes/therapeutic use , Diet, Reducing , Disease Outbreaks , Female , Global Health , Humans , Leptin , Obesity/genetics , Obesity/therapy , PrevalenceABSTRACT
Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease.
Subject(s)
Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/therapy , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/prevention & control , AIDS-Related Opportunistic Infections/therapy , Adult , Cytomegalovirus Infections/prevention & control , Humans , Tissue Transplantation , Viral VaccinesSubject(s)
Antiviral Agents/therapeutic use , Virus Diseases/drug therapy , Anti-HIV Agents/therapeutic use , Drug Therapy, Combination , HIV Infections/drug therapy , Hepatitis, Viral, Human/drug therapy , Herpesviridae Infections/drug therapy , Humans , Papillomaviridae , Papillomavirus Infections/drug therapy , Respiratory Tract Infections/drug therapyABSTRACT
CMV infection and CMV disease can be difficult to differentiate and the diagnosis is usually based on a compatible clinical picture and the results of a diagnostic test for CMV. The only exception to this rule is in HIV-infected patients where fundoscopy is sufficient to diagnose CMV retinitis. Of the current diagnostic tests, qualitative and quantitative PCR, branched DNA and Hybrid Capture, are the most promising. The pp65 antigenemia assay has the disadvantage of being more labor-intensive than the DNA based tests. Preliminary data show that a positive qualitative PCR in a HIV-infected patient has a predictive value for the development of CMV retinitis. However, of the patients positive by qualitative PCR, those with high viral loads in quantitative PCR were at the greatest risk of CMV disease. This might make it possible to identify with great certainty the patients who will go on to develop CMV retinitis, thereby decreasing the number of patients eligible for preemptive or prophylactic therapy and increasing the cost-benefit of this therapeutic measure. Quantitative test might also be useful in monitoring response to therapy, but randomized trials comparing the test are needed. Prophylactic antiviral agents should not be used in seronegative transplant recipients receiving organs from seronegative donors. In high-risk transplant recipients, ganciclovir should be used. CMV vaccines are useful for the protection of babies from CMV seronegative mothers against congenital CMV disease. It also may be useful in seronegative transplant recipients receiving a seropositive donor organ, although the benefit of chemo prophylaxis may surpass that of vaccine. HIV-infected patients with CMV retinitis who relapse under either ganciclovir or foscarnet benefit from subsequent combination therapy, rather than switching to the other drug. However, the cost is high in terms of quality of life. Intravitreal therapy for CMV retinitis is very efficacious, suggesting that drug delivery is a problem in systemic therapy. However, intravitreal therapy does not protect against the development of CMV retinitis in the contralateral eye or from CMV disease elsewhere. Therefore, systemic therapy should be added. CMV disease of the CNS should be diagnosed early and treated agressively, possible with combination therapy. A diagnosis of CMV disease should be based on a compatible clinical picture and the demonstration of CMV in CSF by DNA or antigen assays which are more sensitive than culture.
Subject(s)
Cytomegalovirus Infections , Animals , Antiviral Agents , Cytomegalovirus/immunology , Disease Models, Animal , Drug Resistance, Microbial , Humans , International Cooperation , Viral VaccinesSubject(s)
Antiviral Agents/therapeutic use , Virus Diseases/drug therapy , Antiviral Agents/metabolism , Antiviral Agents/pharmacology , Biotransformation , DNA, Viral/biosynthesis , Drug Resistance, Microbial , Drug Therapy, Combination , Forecasting , Humans , Interferons/therapeutic use , Phosphorylation , Protein Biosynthesis/drug effects , RNA, Viral/biosynthesis , Viral Proteins/metabolism , Virus Diseases/prevention & control , Virus Replication/drug effects , Viruses/enzymologySubject(s)
Herpesviridae Infections/therapy , Adjuvants, Immunologic/therapeutic use , Adult , Antiviral Agents/therapeutic use , Burkitt Lymphoma/prevention & control , Chickenpox/prevention & control , Cytomegalovirus Infections/prevention & control , Female , Herpes Simplex/drug therapy , Herpes Simplex/immunology , Herpes Simplex/prevention & control , Herpes Zoster/prevention & control , Herpesviridae Infections/complications , Herpesviridae Infections/prevention & control , Herpesvirus 4, Human , Humans , Immunization, Passive , Infant , Infant, Newborn , Infectious Mononucleosis/prevention & control , Male , Photochemotherapy , Uterine Cervical Neoplasms/etiology , Viral Vaccines/therapeutic useSubject(s)
Antiviral Agents/therapeutic use , Herpes Genitalis/drug therapy , Animals , Antiviral Agents/pharmacology , Chlorocebus aethiops , Clinical Trials as Topic , Disease Models, Animal , Female , Guinea Pigs , Herpes Genitalis/pathology , Humans , Infant, Newborn , Infant, Newborn, Diseases/microbiology , Male , Mice , National Institutes of Health (U.S.) , Pregnancy , Simplexvirus/drug effects , United StatesSubject(s)
Antiviral Agents/therapeutic use , Amantadine/therapeutic use , Ascorbic Acid/therapeutic use , Dosage Forms , Drug Evaluation , Encephalitis/drug therapy , Hepatitis/drug therapy , Herpes Simplex/drug therapy , Herpes Zoster/drug therapy , Humans , Idoxuridine/therapeutic use , Influenza, Human/drug therapy , Inosine Pranobex/therapeutic use , Interferons/therapeutic use , Levamisole/therapeutic use , Rimantadine/therapeutic use , Subacute Sclerosing Panencephalitis/drug therapy , Trifluridine/therapeutic use , Virus Diseases/drug therapySubject(s)
Antiviral Agents/therapeutic use , Interferons/therapeutic use , Neoplasms/drug therapy , Virus Diseases/drug therapy , Acyclovir , Amantadine/therapeutic use , Bromodeoxyuridine/analogs & derivatives , Bromodeoxyuridine/therapeutic use , Clinical Trials as Topic , Guanine/analogs & derivatives , Guanine/therapeutic use , Hepatitis B/drug therapy , Herpesviridae Infections/drug therapy , Humans , Ketones/therapeutic use , Phosphonoacetic Acid/therapeutic use , Vidarabine/therapeutic useABSTRACT
Infectious viral diseases are an important worldwide problem and as a result of more efficient epidemiological studies and improved techniques of viral diagnosis "new" diseases are periodically identified. More importantly, as we learn to control cancer and perform tissue and organ transplants, the immunosuppressed patient is at greater risk of viral infection. There are currently very few generally accepted antiviral agents, but recent research efforts are encouraging. The status of the approved agents and of those showing the greatest promise is discussed in this article.